Hsp90 inhibitor 17‑AAG inhibits stem cell‑like properties and chemoresistance in osteosarcoma cells via the Hedgehog signaling pathway Corrigendum in /10.3892/or.2023.8593

Shu,Xiong; Liu,Huiqi; Zhen,Rui; Jie,Yongsheng; Chen,Lei; Qi,Hui; Wang,Chao; Wang,Renxian; Chen,Dafu; Ran,Yuliang

doi:10.3892/or.2020.7597

Hsp90 inhibitor 17‑AAG inhibits stem cell‑like properties and chemoresistance in osteosarcoma cells via the Hedgehog signaling pathway

Corrigendum in: /10.3892/or.2023.8593

Authors:
- Xiong Shu
- Huiqi Liu
- Rui Zhen
- Yongsheng Jie
- Lei Chen
- Hui Qi
- Chao Wang
- Renxian Wang
- Dafu Chen
- Yuliang Ran
View Affiliations

Affiliations: Laboratory of Bone Tissue Engineering, Beijing Laboratory of Biomedical Materials, Beijing Research Institute of Orthopaedics and Traumatology, Beijing JiShuiTan Hospital, Beijing 100035, P.R. China, Department of Basic Medical Science, Medical School of Qinghai University, Xining, Qinghai 810016, P.R. China, State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China
Published online on: April 28, 2020 https://doi.org/10.3892/or.2020.7597
Pages: 313-324

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Multiple drug resistance is a major obstacle to the successful treatment of osteosarcoma (OS). Recent studies have demonstrated that a subset of cells, referred to as OS stem cells (OSCs), play a crucial role in the acquisition of multiple drug resistance. Therefore, an improved understanding of OS biology and pathogenesis is required to advance the development of targeted therapies aimed at eradicating this particular subset of cells in order to reverse acquired chemoresistance in OS. The aim of the present study was to assess the anti‑OSC effects of 17‑AAG and determine the underlying molecular mechanism. Heat shock protein 90 expression was found to be increased in sarcosphere cells and was positively associated with cancer stem cell characteristics. In addition, 17‑AAG was able to suppress the stem cell‑like phenotype of OS cells. Mechanistically, 17‑AAG inhibited OSC‑like properties and chemoresistance through glycogen synthase kinase (GSK) 3β inactivation‑mediated repression of the Hedgehog signaling pathway. The findings of the present study provided comprehensive evidence for the inhibition of OSC properties and chemoresistance by 17‑AAG through repression of the GSK3β/Hedgehog signaling pathway, suggesting that 17‑AAG may be a promising therapeutic agent for targeting OSCs.

View Figures

View References

1	Whelan JS and Davis LE: Osteosarcoma, chondrosarcoma, and chordoma. J Clin Oncol. 36:188–193. 2018. View Article : Google Scholar : PubMed/NCBI
2	Isakoff MS, Bielack SS, Meltzer P and Gorlick R: Osteosarcoma: Current treatment and a collaborative pathway to success. J Clin Oncol. 33:3029–3035. 2015. View Article : Google Scholar : PubMed/NCBI
3	Mirabello L, Troisi RJ and Savage SA: Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the surveillance, epidemiology, and end results program. Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
4	Schiavone K, Garnier D, Heymann MF and Heymann D: The heterogeneity of osteosarcoma: The role played by cancer stem cells. Adv Exp Med Biol. 1139:187–200. 2019. View Article : Google Scholar : PubMed/NCBI
5	Brown HK, Tellez-Gabriel M and Heymann D: Cancer stem cells in osteosarcoma. Cancer Lett. 386:189–195. 2017. View Article : Google Scholar : PubMed/NCBI
6	Yan GN, Lv YF and Guo QN: Advances in osteosarcoma stem cell research and opportunities for novel therapeutic targets. Cancer Lett. 370:268–274. 2016. View Article : Google Scholar : PubMed/NCBI
7	Clevers H: The cancer stem cell: Premises, promises, and challenges. Nat Med. 17:313–319. 2011. View Article : Google Scholar : PubMed/NCBI
8	Shackleton M, Quintana E, Fearon ER and Morrison SJ: Heterogeneity in cancer: Cancer stem cells versus clonal evolution. Cell. 138:822–829. 2009. View Article : Google Scholar : PubMed/NCBI
9	Fujiwara T, Katsuda T, Hagiwara K, Kosaka N, Yoshioka Y, Takahashi RU, Takeshita F, Kubota D, Kondo T, Ichikawa H, et al: Clinical relevance and therapeutic significance of microRNA-133a expression profiles and functions in malignant osteosarcoma-initiating cells. Stem Cells. 32:959–973. 2014. View Article : Google Scholar : PubMed/NCBI
10	Honoki K, Fujii H, Kubo A, Kido A, Mori T, Tanaka Y and Tsujiuchi T: Possible involvement of stem-like populations with elevated ALDH1 in sarcomas for chemotherapeutic drug resistance. Oncol Rep. 24:501–505. 2010. View Article : Google Scholar : PubMed/NCBI
11	Adhikari AS, Agarwal N, Wood BM, Porretta C, Ruiz B, Pochampally RR and Iwakuma T: CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res. 70:4602–4612. 2010. View Article : Google Scholar : PubMed/NCBI
12	Tian J, Li X, Si M, Liu T and Li J: CD271+ osteosarcoma cells display stem-like properties. PLoS One. 9:e985492014. View Article : Google Scholar : PubMed/NCBI
13	Qi XT, Li YL, Zhang YQ, Xu T, Lu B, Fang L, Gao JQ, Yu LS, Zhu DF, Yang B, et al: KLF4 functions as an oncogene in promoting cancer stem cell-like characteristics in osteosarcoma cells. Acta Pharmacol Sin. 40:546–555. 2019. View Article : Google Scholar : PubMed/NCBI
14	Lee YH, Yang HW, Yang LC, Lu MY, Tsai LL, Yang SF, Huang YF, Chou MY, Yu CC and Hu FW: DHFR and MDR1 upregulation is associated with chemoresistance in osteosarcoma stem-like cells. Oncol Lett. 14:171–179. 2017. View Article : Google Scholar : PubMed/NCBI
15	Dong J, Bi B, Zhang L and Gao K: GLIPR1 inhibits the proliferation and induces the differentiation of cancer-initiating cells by regulating miR-16 in osteosarcoma. Oncol Rep. 36:1585–1591. 2016. View Article : Google Scholar : PubMed/NCBI
16	Qu H, Xue Y, Lian W, Wang C, He J, Fu Q, Zhong L, Lin N, Lai L, Ye Z and Wang Q: Melatonin inhibits osteosarcoma stem cells by suppressing SOX9-mediated signaling. Life Sci. 207:253–264. 2018. View Article : Google Scholar : PubMed/NCBI
17	Maloney A and Workman P: HSP90 as a new therapeutic target for cancer therapy: The story unfolds. Expert Opin Biol Ther. 2:3–24. 2002. View Article : Google Scholar : PubMed/NCBI
18	Neckers L: Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med. 8 (4 Suppl):S55–S61. 2002. View Article : Google Scholar : PubMed/NCBI
19	Barker CR, Hamlett J, Pennington SR, Burrows F, Lundgren K, Lough R, Watson AJ and Jenkins JR: The topoisomerase II-Hsp90 complex: A new chemotherapeutic target? Int J Cancer. 118:2685–2693. 2006. View Article : Google Scholar : PubMed/NCBI
20	White PT, Subramanian C, Zhu Q, Zhang H, Zhao H, Gallagher R, Timmermann BN, Blagg BS and Cohen MS: Novel HSP90 inhibitors effectively target functions of thyroid cancer stem cell preventing migration and invasion. Surgery. 159:142–152. 2016. View Article : Google Scholar : PubMed/NCBI
21	Kim HB, Lee SH, Um JH, Kim MJ, Hyun SK, Gong EJ, Oh WK, Kang CD and Kim SH: Sensitization of chemo-resistant human chronic myeloid leukemia stem-like cells to Hsp90 inhibitor by SIRT1 inhibition. Int J Biol Sci. 11:923–934. 2015. View Article : Google Scholar : PubMed/NCBI
22	Nanta R, Shrivastava A, Sharma J, Shankar S and Srivastava RK: Inhibition of sonic hedgehog and PI3K/Akt/mTOR pathways cooperate in suppressing survival, self-renewal and tumorigenic potential of glioblastoma-initiating cells. Mol Cell Biochem. 454:11–23. 2019. View Article : Google Scholar : PubMed/NCBI
23	Kobune M, Takimoto R, Murase K, Iyama S, Sato T, Kikuchi S, Kawano Y, Miyanishi K, Sato Y, Niitsu Y and Kato J: Drug resistance is dramatically restored by hedgehog inhibitors in CD34+ leukemic cells. Cancer Sci. 100:948–955. 2009. View Article : Google Scholar : PubMed/NCBI
24	Yoon C, Park DJ, Schmidt B, Thomas NJ, Lee HJ, Kim TS, Janjigian YY, Cohen DJ and Yoon SS: CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance. Clin Cancer Res. 20:3974–3988. 2014. View Article : Google Scholar : PubMed/NCBI
25	Mastrangelo E and Milani M: Role and inhibition of GLI1 protein in cancer. Lung Cancer (Auckl). 9:35–43. 2018.PubMed/NCBI
26	Pan Y, Shu X, Sun L, Yu L, Sun L, Yang Z and Ran Y: miR-196a-5p modulates gastric cancer stem cell characteristics by targeting Smad4. Int J Oncol. 50:1965–1976. 2017. View Article : Google Scholar : PubMed/NCBI
27	Schmittgen TD, Zakrajsek BA, Mills AG, Gorn V, Siner MJ and Reed MW: Quantitative reverse transcription polymerase chain reaction to study mRNA decay: Comparison of end point and realtime methods. Anal Biochem. 285:194–204. 2000. View Article : Google Scholar : PubMed/NCBI
28	Martins-Neves SR, Paiva-Oliveira DI, Wijers-Koster PM, Abrunhosa AJ, Fontes-Ribeiro C, Bovee JV, Cleton-Jansen AM and Gomes CM: Chemotherapy induces stemness in osteosarcoma cells through activation of Wnt/β-catenin signaling. Cancer Lett. 370:286–295. 2016. View Article : Google Scholar : PubMed/NCBI
29	Yu L, Fan Z, Fang S, Yang J, Gao T, Simoes BM, Eyre R, Guo W and Clarke RB: Cisplatin selects for stem-like cells in osteosarcoma by activating notch signaling. Oncotarget. 7:33055–33068. 2016. View Article : Google Scholar : PubMed/NCBI
30	Trnski D, Sabol M, Gojević A, Martinić M, Ozretić P, Musani V, Ramić S and Levanat S: GSK3β and Gli3 play a role in activation of Hedgehog-Gli pathway in human colon cancer-Targeting GSK3β downregulates the signaling pathway and reduces cell proliferation. Biochim Biophys Acta. 1852:2574–2584. 2015. View Article : Google Scholar : PubMed/NCBI
31	Izadpanah S, Shabani P, Aghebati-Maleki A, Baghbanzadeh A, Fotouhi A, Bisadi A, Aghebati-Maleki L and Baradaran B: Prospects for the involvement of cancer stem cells in the pathogenesis of osteosarcoma. J Cell Physiol. 235:4167–4182. 2020. View Article : Google Scholar : PubMed/NCBI
32	Liu B, Ma W, Jha RK and Gurung K: Cancer stem cells in osteosarcoma: Recent progress and perspective. Acta Oncol. 50:1142–1150. 2011. View Article : Google Scholar : PubMed/NCBI
33	Basu-Roy U, Basilico C and Mansukhani A: Perspectives on cancer stem cells in osteosarcoma. Cancer Lett. 338:158–167. 2013. View Article : Google Scholar : PubMed/NCBI
34	Sauvageot CM, Weatherbee JL, Kesari S, Winters SE, Barnes J, Dellagatta J, Ramakrishna NR, Stiles CD, Kung AL, Kieran MW and Wen PY: Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. Neuro Oncol. 11:109–121. 2009. View Article : Google Scholar : PubMed/NCBI
35	Newman B, Liu Y, Lee HF, Sun D and Wang Y: HSP90 inhibitor 17-AAG selectively eradicates lymphoma stem cells. Cancer Res. 72:4551–4561. 2012. View Article : Google Scholar : PubMed/NCBI
36	Amini S, Fathi F, Mobalegi J, Sofimajidpour H and Ghadimi T: The expressions of stem cell markers: Oct4, Nanog, Sox2, nucleostemin, Bmi, Zfx, Tcl1, Tbx3, Dppa4, and Esrrb in bladder, colon, and prostate cancer, and certain cancer cell lines. Anat Cell Biol. 47:1–11. 2014. View Article : Google Scholar : PubMed/NCBI
37	Sarto C, Binz PA and Mocarelli P: Heat shock proteins in human cancer. Electrophoresis. 21:1218–1226. 2000. View Article : Google Scholar : PubMed/NCBI
38	Staufer K and Stoeltzing O: Implication of heat shock protein 90 (HSP90) in tumor angiogenesis: A molecular target for anti-angiogenic therapy? Curr Cancer Drug Targets. 10:890–897. 2010. View Article : Google Scholar : PubMed/NCBI
39	Zuehlke A and Johnson JL: Hsp90 and co-chaperones twist the functions of diverse client proteins. Biopolymers. 93:211–217. 2010. View Article : Google Scholar : PubMed/NCBI
40	Zhao Z, Jia Q, Wu MS, Xie X, Wang Y, Song G, Zou CY, Tang Q, Lu J, Huang G, et al: Degalactotigonin, a natural compound from solanum nigrum L., inhibits growth and metastasis of osteosarcoma through GSK3β inactivation-mediated repression of the hedgehog/Gli1 pathway. Clin Cancer Res. 24:130–144. 2018. View Article : Google Scholar : PubMed/NCBI
41	Stecca B, Mas C, Clement V, Zbinden M, Correa R, Piguet V, Beermann F and Ruiz I Altaba A: Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways. Proc Natl Acad Sci USA. 104:5895–5900. 2007. View Article : Google Scholar : PubMed/NCBI
42	Wang Y, Ding Q, Yen CJ, Xia W, Izzo JG, Lang JY, Li CW, Hsu JL, Miller SA, Wang X, et al: The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell. 21:374–387. 2012. View Article : Google Scholar : PubMed/NCBI
43	Das S, Harris LG, Metge BJ, Liu S, Riker AI, Samant RS and Shevde LA: The hedgehog pathway transcription factor GLI1 promotes malignant behavior of cancer cells by up-regulating osteopontin. J Biol Chem. 284:22888–22897. 2009. View Article : Google Scholar : PubMed/NCBI
44	Jiang J and Hui CC: Hedgehog signaling in development and cancer. Dev Cell. 15:801–812. 2008. View Article : Google Scholar : PubMed/NCBI
45	Ruiz I Altaba A: Gli proteins and Hedgehog signaling: Development and cancer. Trends Genet. 15:418–425. 1999. View Article : Google Scholar : PubMed/NCBI
46	Ng JM and Curran T: The Hedgehog's tale: Developing strategies for targeting cancer. Nat Rev Cancer. 11:493–501. 2011. View Article : Google Scholar : PubMed/NCBI
47	Katoh Y and Katoh M: Integrative genomic analyses on GLI1: Positive regulation of GLI1 by Hedgehog-GLI, TGFbeta-Smads, and RTK-PI3K-AKT signals, and negative regulation of GLI1 by Notch-CSL-HES/HEY, and GPCR-Gs-PKA signals. Int J Oncol. 35:187–192. 2009. View Article : Google Scholar : PubMed/NCBI
48	Tang QL, Xie XB, Wang J, Chen Q, Han AJ, Zou CY, Yin JQ, Liu DW, Liang Y, Zhao ZQ, et al: Glycogen synthase kinase-3β, NF-KB signaling, and tumorigenesis of human osteosarcoma. J Nat Cancer Inst. 104:749–63. 2012. View Article : Google Scholar : PubMed/NCBI
49	Hur EM and Zhou FQ: GSK3 signaling in neural development. Nat Rev Neurosci. 11:539–551. 2010. View Article : Google Scholar : PubMed/NCBI
50	Beurel E, Grieco SF and Jope RS: Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases. Pharmacol Ther. 148:114–131. 2015. View Article : Google Scholar : PubMed/NCBI
51	Riobó NA, Lu K, Ai X, Haines GM and Emerson CP Jr: Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signaling. Proc Natl Acad Sci USA. 103:4505–4510. 2006. View Article : Google Scholar : PubMed/NCBI
52	Feng X, Xu W, Li Z, Song W, Ding J and Chen X: Immunomodulatory Nanosystems. Adv Sci (Weinh). 6:19001012019. View Article : Google Scholar : PubMed/NCBI
53	Yin F, Wang Z, Jiang Y, Zhang T, Wang Z, Hua Y, Song Z, Liu J, Xu W, Xu J, et al: Reduction-responsive polypeptide nanomedicines significantly inhibit progression of orthotopic osteosarcoma. Nanomedicine. 23:1020852020. View Article : Google Scholar : PubMed/NCBI
54	Ding J, Chen J, Gao L, Jiang Z, Zhang Y, Li M, Xiao Q, Lee SS and Chen X: Engineered nanomedicines with enhanced tumor penetration. Nano Today. 29:1008002019. View Article : Google Scholar